Wang Lai

Global Head of R&D Wang Lai sells entire 5,000-share stake in ONC for $1.8M on 2025-09-09, exiting completely as stock rallies +16.5% in 30 days.

Wang Lai, Global Head of R&D at BeOne Medicines, executed a complete liquidation of his 5,000-share position in ONC on 2025-09-09 at $350.06, raising $1,750,311.50. The sale occurs against a backdrop of strong recent momentum: the stock has risen 16.5% over the prior 30 days and 24.5% over the prior 90 days, trading only 4.4% below its 52-week high of $351.13. The timing is noteworthy because his cross-ticker track record shows a 100.00% well-timed rate on 11 prior sells (average 90-day return of -16.2%), yet his prior four sales at ONC specifically (in late July) have not yet shown negative 90-day returns to confirm a timing pattern at this ticker. This full exit by the R&D leader merits attention: while fundamentals show the company is large ($480.1B market cap) and growing revenue by 55.0%, it remains unprofitable on an annual basis, and the insider's complete departure of holdings removes a key technology officer's equity stake precisely when momentum is strongest.

Wang Lai (Global Head of R&D) sold entire 4,300-share stake for $1.3M at avg $302.65 on 2025-07-29/30

Wang Lai executed 4 separate sales totaling 4,300 shares for $1,301,375.41, completely liquidating his position in BeOne Medicines. The transactions occurred at prices between $302.00 and $305.00 per share, near the stock's 52-week high of $305.74, and at a blended average of $302.65 versus the current price of $301.13. Across his cross-ticker track record, Wang's 7 prior sales had a 90-day well-timed rate of 100.00%, indicating his historical sells have consistently preceded downward price moves. BeOne's fundamentals show $1.1B in latest-quarter revenue with +55.0% annual growth, though the company posted negative net income on a full-year basis, limiting the conviction-level clarity a full liquidation might otherwise suggest.

Global Head of R&D Wang Lai sells entire 5.0K share position at $257.23 blended avg; stock down -14.1% (30d), -20.9% (90d) since filing

Wang Lai, Global Head of R&D at BeiGene, executed 6 separate sales on 2025-02-21 totaling 5,000 shares for $1,286,174.03, liquidating his entire holdings at a blended average price of $257.23. The timing is notable: the stock has declined -14.1% over the past 30 days and -20.9% over the past 90 days, and currently trades at $184.71 — 24.9% below the 52-week high. His prior sell at this ticker on 2024-09-27 exhibited a 90-day return of -16.2%, and his cross-ticker track record shows 100% well-timed sells at the 90-day mark (avg 90d return -16.2%). The company reported $1,001,599,000 revenue in the latest quarter with annual growth of +73.6%, but remains unprofitable (net income $-121,350,000). The complete liquidation of a key R&D executive's position amid ongoing losses and deteriorating post-filing stock performance warrants investor scrutiny.

Global Head of R&D Wang Lai sells 5,000 shares at $220.35; complete exit from 5.0K share position.

Wang Lai, Global Head of R&D at BeiGene (BGNE), executed a complete liquidation of his shareholding on September 27, 2024, selling 5,000 shares at $220.35 for $1,101,774.00, reducing his post-transaction holdings to 0 shares. This full exit occurs during a period of notable stock appreciation: the 90-day change shows +56.1% and the 30-day change shows +20.4%, with the current price $230.98 near the 52-week high of $230.98. BeiGene's fundamentals reveal substantial revenue growth (annual revenue growth of +73.6%) and a large $929.2M in latest-quarter revenue, yet the company remains unprofitable, posting a net income of $-120.4M over its most recent full fiscal year. The complete exit of a long-term insider holding in a high-ranking R&D position while the stock is near 52-week highs and the company is unprofitable warrants attention to whether this signals a shift in leadership conviction regarding the company's current valuation or near-term prospects.